Nantahala Capital advised by Akin Gump on Soleno Investment
Akin Gump represented Nantahala Capital Management in its securities purchase agreement, alongside co-investors Abingworth
Nantahala Capital advised by Akin Gump on Soleno Investment Akin Gump represented Nantahala Capital Management in its securities purchase agreement, alongside co-investors Abingworth LLP and Vivo Capital, LLC, for up to $60 million, with Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. In accordance with...
Nantahala Capital advised by Akin Gump on Soleno Investment
Akin Gump represented Nantahala Capital Management in its securities purchase agreement, alongside co-investors Abingworth LLP and Vivo Capital, LLC, for up to $60 million, with Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases.
In accordance with the terms of the contract, the investors agreed to pay $10 million in return for rights to buy common shares. It is done after the business pronouncement enrolment completion in Study C602's randomized withdrawal period, expected to happen in the first quarter of 2023.
Corporate Partner Shar Ahmed, and senior counsel Alexandra Reuss, a handled the transaction.
Click to know more about Akin Gump